• By Donald Zuhn —

    Federal Circuit SealLast month, in Amgen Inc. v. Coherus BioSciences Inc., the Federal Circuit affirmed a decision by the U.S. District Court for the District of Delaware dismissing a complaint filed by Amgen Inc. and Amgen Manufacturing Ltd. against Coherus BioSciences Inc. for failure to state a claim.  Amgen had filed suit against Coherus for infringement of U.S. Patent No. 8,273,707.

    The '707 patent is directed to methods of purifying proteins using hydrophobic interaction chromatography ("HIC"), in which a solid, hydrophobic matrix is used to separate proteins on the basis of hydrophobic interactions between the hydrophobic moieties of the protein and insoluble, immobilized hydrophobic groups on the matrix.  The process disclosed in the '707 patent increases an HIC column's dynamic capacity, which is the maximum amount of protein in a solution which can be loaded onto a column without significant leakage (or breakthrough) of the protein into the solution phase before elution.  Prior art HIC columns used buffers with higher salt concentrations to increase dynamic capacity, but such methods also resulted in protein instability, increased viscosity of a solution, increased formation of aggregates, protein loss due to dilution and filtration of the protein after elution from the column, and reduced protein purity.  According to the '707 patent, the claimed process "provides combinations of salts useful for increasing the dynamic capacity of an HIC column compared with the dynamic capacity of the column using separate salts alone."  Representative claim 1 recites:

    1.  A process for purifying a protein on a hydrophobic interaction chromatography column such that the dynamic capacity of the column is increased for the protein comprising
        mixing a preparation containing the protein with a combination of a first salt and a second salt,
        loading the mixture onto a hydrophobic inter-action chromatography column, and eluting the protein,
        wherein the first and second salts are selected from the group consisting of citrate and sulfate, cit-rate and acetate, and sulfate and acetate, respectively, and
        wherein the concentration of each of the first salt and the second salt in the mixture is between about 0.1 M and about 1.0.

    During prosecution of the application that issued as the '707 patent, the Examiner rejected the claims as obvious in view of U.S. Patent No. 5,231,178 ("Holtz").  Amgen responded to the rejection by arguing that Holtz neither taught nor suggested using combinations of salts nor the particular salts recited in the claims.  Amgen also noted that the claimed invention was directed to increasing the dynamic capacity of an HIC column, and that Holtz did not teach dynamic capacity.  In addition, Amgen provided a declaration from one of the inventors stating that using a sulfate/citrate or sulfate/acetate salt combination resulted in substantial increases in the dynamic capacity of a HIC column as compared to using a single salt.  After the Examiner again rejected the claims, Amgen reiterated that Holtz does not disclose a combination of salts and does not disclose enhancing the dynamic capacity of an HIC column, and also pointed out that "merely adding a second salt" would not result in the invention.  The Examiner thereafter allowed the claims.

    In 2016, Coherus filed an abbreviated Biologic License Application ("aBLA") seeking FDA approval to market a biosimilar version of Amgen's pegfilgrastim product Neulasta.  After exchanging information pursuant to the Biologics Price Competition and Innovation Act ("BPCIA"), the parties determined that the '707 patent should be included in Amgen's infringement suit against Coherus.  In particular, the aBLA filed by Coherus indicates that its pegfilgrastim manufacturing process utilizes several chromatography steps, one of which involves a chromatography buffer containing a salt combination, albeit not one of the combinations specifically recited in the claims.

    Based on Coherus' aBLA, Amgen filed suit against Coherus alleging infringement of the '707 patent under the doctrine of equivalents.  Coherus responded by moving to dismiss Amgen's complaint under Fed. R. Civ. P. 12(b)(6).  Noting that Amgen had distinguished Holtz by arguing that the reference did not disclose "one of the particular, recited combinations of salts," a magistrate judge recommended that Coherus' motion be granted because "prosecution history estoppel bars Amgen from now attempting to reassert surrendered ground involving other combinations of salts."  The District Court adopted the magistrate judge's recommendation and granted Coherus' motion to dismiss.  Amgen appealed the dismissal to the Federal Circuit.

    In affirming the District Court's dismissal of Amgen's complaint, the Federal Circuit found that "during prosecution of the '707 patent, Amgen clearly and unmistakably surrendered salt combinations other than the particular combinations recited in the claims," and determined that "[p]rosecution history estoppel thus bars Amgen from succeeding on its infringement claim under the doctrine of equivalents."  Amgen, however, argued that during prosecution it had distinguished Holtz on the basis that this reference failed to disclose increasing dynamic capacity and failed to disclose any salt combinations at all.  The Federal Circuit noted that:

    Amgen asserted three bases for distinguishing Holtz: (1) "[n]o combinations of salts [are] taught nor suggested in the Holtz et al. patent"; (2) "nor [are] the particular combinations of salts recited in the pending claims taught nor suggested in [Holtz],"; and (3) "[t]here is no description or suggestion in Holtz et al. for the use of any combination of salts to increase the dynamic capacity of a HIC."

    Citing PODS, Inc. v. Porta Stor, Inc., 484 F.3d 1359, 1367 (Fed. Cir. 2007), the Federal Circuit also noted that "where a patent applicant sets forth multiple bases to distinguish between its invention and the cited prior art, the separate arguments [can] create separate estoppels as long as the prior art was not distinguished based on the combination of these various grounds."  The Court concluded that "Amgen did not rely on the combination of its asserted grounds to distinguish Holtz," and that "while Amgen did assert multiple reasons for why Holtz is distinguishable, our precedent instructs that estoppel can attach to each argument."  The Court therefore determined that in the instant case, "prosecution history estoppel applies to the 'particular combinations' ground regardless of the other two arguments Amgen made."

    Amgen also argued that prosecution history should not apply in the instant case because the response filed prior to allowance of the claims did not contain the argument that Holtz failed to disclose the particular claimed salt combinations.  Explaining that "[t]here is no requirement that argument-based estoppel apply only to arguments made in the most recent submission before allowance," the Federal Circuit stated that "[w]e see nothing in Amgen's final submission that disavows the clear and unmistakable surrender of unclaimed salt combinations made in Amgen's [earlier] response."  The Federal Circuit therefore determined that the District Court did not err in determining that prosecution history estoppel barred Amgen from succeeding on its infringement claim under the doctrine of equivalents, and affirmed the District Court's order dismissing Amgen's complaint for failure to state a claim.

    Amgen Inc. v. Coherus BioSciences Inc. (Fed. Cir. 2019)
    Panel: Circuit Judges Reyna, Hughes, and Stoll
    Opinion by Circuit Judge Stoll

  • CalendarAugust 15, 2019 – Technology Center 2800 customer partnership meeting (U.S. Patent and Trademark Office) – 11:30 am to 4:30 pm (ET) on 

    August 20, 2019 – "Section 101 Reform: Prospects and Pitfalls" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    August 29, 2019 – "How Late Is Too Late? Setting the Timeline for Patent Protection" (Fitch Even) – 12:00 to 1:00 pm (EDT)

    October 3-4, 2019 – Paragraph IV Disputes Master Symposium (American Conference Institute) – Chicago IL

  • Fitch EvenFitch Even will be offering a webinar entitled "How Late Is Too Late? Setting the Timeline for Patent Protection" on August 29, 2019 from 12:00 to 1:00 pm (EDT).  Mark A. Borsos and Vincent R. Meyer of Fitch Even will explore considerations affecting the timing of patent filings and what to do if an inventor's prior actions have potentially put their patent rights in jeopardy, and will also discuss the following:

    • Supreme Court and Federal Circuit decisions regarding statutory bars
    • When an invention is "ready for patenting"
    • Potential scenarios that could endanger patent rights
    • Factors that may weigh for and against patentability once an invention has been disclosed or offered for sale
    • Strategies for coordinating patent filings with development efforts

    While there is no cost to participate in the program, advance registration is required.  Those interested in attending the webinar can register here.

  • By Kevin E. Noonan —

    Persea_americana_fruit_2The avocado, having gained popularity (at least in the U.S.) as a convenient (and delicious) vehicle for consuming otherwise not particularly healthful corn chips, has more recently been hailed as a "superfood" when consumed in diets as a healthy form of fat.  Recently, the avocado joined the ranks of other plants important for human nutrition (see, for example, "Genomic Sequence of Strawberry Determined"; "Genetic Analyses of Sweet Potato Genome Sheds Light on Speciation and Global Dispersion Patterns"; "Durum Wheat Genome Revealed"; and "Genetic Assessment of Squash Genomes in Related Species") in having the sequence of its genome determined, with concomitant explication of its evolutionary history and relationship to other members of the plant kingdom.

    This achievement was reported in the Proceedings of the National Academy of Sciences USA, in a paper entitled "The avocado genome informs deep angiosperm phylogeny, highlights introgressive hybridization, and reveals pathogen-influenced gene space adaptation" (https://doi.org/10.1073/pnas.1822129116) by an international group of researchers.*  The avocado, Persea americana, is a member of the Lauraceae family, otherwise known for the spices cinnamon, bay leaves, and sassafras (gumbo filé).  Avocadoes anciently diverged from other angiosperms, and their magnoliid clade comprises 11,000 total species, which the authors assert is "minuscule in comparison to the dominant eudicot and monocot flowering plant lineages, comprising about 285,000 species combined."  Conventional genetic analyses had not established the avocados' phylogenetic position relative to eudicots and monocots.

    The predominant avocado is the Mexican avocado, P. americana var. drymifolia, comprising three varieties:  the Mexican, Guatemalan, and West Indian varieties.  Familiar to many afficianados is the Hass cultivar, which is a hybrid between the Guatemalan and Mexican races and is typically grafted onto Mexican race rootstock.  Worldwide, 90% of cultivated avocado corresponds to the cultivar Hass; surprisingly, the Hass cultivar is of recent (20th century) origin.

    The authors sequenced Hass and Mexican cultivars as reference genomes, and resequenced three other cutivars (vars. drymifolia, guatemalensis, and americana), as well as wild avocados of the West Indian variety (P. america1na var. costaricensis), and Persea shiedeana (the edible coyo), a species that is relatively closely related to P. americana.  The avocado genome comprises 12 chromosomes, and these authors report that the genome size of P. americana var. drymifolia is 920 Mb in size, while the P. americana Hass cultivar has a 912.6 Mb estimated genome size.  Analysis of protein coding sequences was based on a comparison with protein sequences from the following angiosperm species:  Sorghum bicolor (33,032 proteins), Vitis vinifera (26,343 proteins), Solanum lycopersicum (34,727 proteins), and Arabidopsis thaliana (27,416 proteins).  These authors reported an estimated number of protein-coding genes in each genome:  22,441 protein-coding genes from the Mexican genome and 24,616 protein-coding genes from the Hass cultivar genome.

    Turning to genome structure, the authors used principal component analysis of genome-wide single nucleotide polymorphisms (SNPs) to show relative uniformity in Costa Rican/West Indian/Guatemalan cultivars but strong heterogeneity within the Mexican subpopulation.  The paper reported 5,050 SNP markers, distributed as follows:

    Table

    Figure 2AResults of these analyses of the Hass cultivar were intermediate between the Guatemalan and Mexican subpopulations, which was in agreement with the hybrid nature of this variety.  Also consistent with the recent appearance of the Hass cultivar, its genome showed significant (39%) introgression of DNA having Guatamalan variety structure into a Mexican genomic background.  Haas cultivar Chromosome 4 illustrates these analyses, demonstrating that a "huge" Guatemalan block, which could encompass an entire chromosomal arm, is present in the Hass genome.  Figure 2A (at right) in the article illustrates a 22 megabase (Mb) stretch of DNA on chromosome 4 exemplifyng genomic introgression from the Guatemalan avocado race (var. guatemalensis) into a Mexican (var. drymifolia) genetic background.

    The authors further report that the relatively long length of this Guatemalan-derived block is uninterrupted by recombination, reflecting the extremely recent hybrid origin of the cultivar.

    Further, genomic analysis revealed evidence of two "ancient" polyploidy events, which the authors report are lineage-specific and both postdate the divergence of the avocado from common ancestry with other angiosperm species.  Avocado divergence from other species appears to have occurred from 7.4 to 3.8 million years ago.  Unfortunately, these relationships could not be unambiguously resolved because the outcome varied with the way the analysis was performed.  Based on comparison of protein sequences, for example, avocado was resolved as a sister to monocots plus eudicots (i.e., branching occurred before their divergence from each other), whereas from analysis of coding sequences avocado was placed as sister to monocots only.

    The authors also reported the phenotypic effects of genome structure, specifically the occurrence of tandem duplications, on gene expression related to potentially important metabolic responses.  Enrichment of tandem duplications was found in chromosomal regions that the authors contend could be related to recent adaptation against fungal pathogens.  On the other hand, ancient polyploid duplicates were enriched with "transcriptional regulatory functions reflective of core physiological and developmental processes" (specifically, "among 2,433 total polyploid duplicates, regulation of transcription, DNA-templated was significantly overrepresented by 352 genes").  Transcriptional activity in tandem duplicates was found to increase following anthracnose infection, the authors positing that some of the up-regulated genes could be related to defense responses.  These included genes involved in phenylpropanoid biosynthesis and closely related pathways that are significantly enriched among tandem duplicates.  The authors further state:

    This functional enrichment in a long-lived tree may have evolved in response to pathogen infection, including Colletotrichum (anthracnose) and Phytophthora cinnamomi (avocado root rot), both of which are reported to activate the phenylpropanoid biosynthetic pathways in avocado.  . . .  Several . . . functional enrichments among avocado tandems (for example, 1,3-beta-D-glucan synthase activity and regulation of cell shape) relate to callose synthase activity, a recently discovered avocado defense mechanism against P. cinnamomi.  Other significantly enriched [metabolic pathways] include phenylpropanoid metabolic process, lignin biosynthetic process, and UDP-glycosyltransferase activity, categories directly or closely related to phenylpropanoid biosynthesis.  The lignin functional enrichment, for example, includes diverse tandemly duplicated genes involved in many pathway-interrelated processes, including homologs of both biosynthetic and regulatory genes encoding hydroxycinnamoyl-CoA shikimate/quinate hydroxycinnamoyl transferase (HCT), cinnamyl alcohol dehydrogenase 5 (CAD5), laccase 17 (LAC17), caffeate o-methyltransferase 1 (COMT1), peroxidase 52 (PRX52), NAC domain containing protein 12 (NAC012), and NAC secondary wall thickening promoting factor 1 (NST1).  As could be expected from the above, the [metabolic pathways] involved in defense response and defense response to fungus are significantly enriched among tandem duplicates, as has been discovered for other plant genomes, and involving many different gene families and responses.  Tandem O-methyltransferases homologous to COMT1 may also contribute to synthesis of the phenylpropanoid derivative and insecticide estragole, which is largely responsible for the anise-like leaf scent and fruit taste of many avocado cultivars, particularly of the Mexican race.  Another relevant enriched . . . category among tandems is ethylene-activated signaling pathway, which annotates many different transcription factor duplicates.  Ethylene signaling factors such as ERF1 (represented by 2 homologs) are heavily involved in pathogen-induced responses, including to infection by Colletotrichum and other necrotrophic fungi.  Also identified are 3 homologs of EIN3, a transcription factor that initiates downstream ethylene responses, including fruit ripening.  Avocado fruit matures on the tree in a process that involves ethylene synthesis and signaling, while it does not ripen until harvested—a desirable trait that allows growers to delay harvesting for several months.

    The authors characterize tandem duplicates as "evolutionarily recent 'tuning knobs' in the genome adaptive landscape[]" of the avocado species:

    [M]ost tandem duplicates in the genome are expected to be of more recent origin, having been generated by ongoing gene birth–death–innovation processes that operate in all eukaryotic genomes.  As such, sub- or neofunctionalized tandem duplicates that survive the usual fate of duplicated genes—pseudogenization—should be enriched in functions that fine-tune a given species' recent selective environment.  In the case of avocado, response to fungal pathogens is precisely reflected in its tandemly duplicated gene complement.

    The authors conclude their report with a concise explanation of its significance:

    Our genomes of Mexican and Hass avocados provide the requisite resources for genome-wide association studies to identify important traits among natural avocado genetic diversity present in Mesoamerica, to develop genome-assisted breeding and genetic modification efforts crucial for the improvement of this long-life-cycle crop, to fight threatening avocado diseases, and to optimize growth and desirable phenotypic traits.

    * Martha Rendón-Anayaa,b,1,
    Enrique Ibarra-Laclettea,c,1,
    Alfonso Méndez-Bravoa,d,
    Tianying Lane,
    Chunfang Zhengf,
    Lorenzo Carretero-Pauletg,
    Claudia Anahí Perez-Torresa,c,
    Alejandra Chacón-Lópeza,
    Gustavo Hernandez-Guzmána,h,i,
    Tien-Hao Change,
    Kimberly M. Farre,
    Brad Barbazukj,
    Srikar Chamalak,
    Marek Mutwill,
    Devendra Shivharel,
    David Alvarez-Poncem,
    Neena Mittern,
    Alice Haywardn,
    Stephen Fletchern,
    Julio Rozaso,p,
    Alejandro Sánchez Graciao,p,
    David Kuhnq,
    Alejandro F. Barrientos-Priegor,
    Jarkko Salojärvil,
    Pablo Librados,t,
    David Sankofff,
    Alfredo Herrera-Estrellaa,
    Victor A. Alberte,l,2, and
    Luis Herrera-Estrellaa,u,2

    aUnidad de Genomica Avanzada/Langebio, Centro de Investigación y de Estudios Avanzados, Irapuato 36821, México; bDepartment of Plant Biology, Uppsala BioCenter, Swedish University of Agricultural Sciences, SE-750 07 Uppsala, Sweden; cRed de Estudios Moleculares Avanzados, Instituto de Ecología A.C., 91070 Xalapa, México; dEscuela Nacional de Estudios Superiores, Laboratorio Nacional de Análisis y Síntesis Ecológica, Universidad Nacional Autónoma de México, 58190 Morelia, México; eDepartment of Biological Sciences, University at Buffalo, Buffalo, NY 14260; fDepartment of Mathematics and Statistics, University of Ottawa, Ottawa, ON, Canada K1N 6N5; gCenter for Plant Systems Biology, Vlaams Instituut voor Biotechnologie (VIB), University of Ghent, 9052 Ghent, Belgium; hDepartamento de Alimentos, Universidad de Guanajuato, 36500 Irapuato, México; iDivisión de Ciencias de la Vida, Universidad de Guanajuato, 36500 Irapuato, México; jDepartment of Biology, University of Florida, Gainesville, FL 32611; kDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32610; lSchool of Biological Sciences, Nanyang Technological University, Singapore 637551; mDepartment of Biology, University of Nevada, Reno, NV 89557; nCentre for Horticultural Science, Queensland Alliance for Agriculture and Food Innovation, The University of Queensland, St. Lucia, QLD 4072, Australia; oDepartament de Genètica, Microbiologia i Estadística, Universitat de Barcelona, 08007 Barcelona, Spain; pInstitut de Recerca de la Biodiversitat, Universitat de Barcelona, 08007 Barcelona, Spain; qSubtropical Horticulture Research Station, Agricultural Research Service, US Department of Agriculture, Miami, FL 33158; rPosgrado en Horticultura, Departamento de Fitotecnia, Universidad Autónoma Chapingo, 56230 Texcoco, México; sCentre for GeoGenetics, Natural History Museum of Denmark, 1017 Copenhagen, Denmark; tLaboratoire d'Anthropobiologie Moléculaire et d'Imagerie de Synthèse, CNRS Unité Mixte de Recherche 5288, Université de Toulouse, Université Paul Sabatier, 31330 Toulouse, France; uDepartment of Plant and Soil Science, Texas Tech University, Lubbock, TX 79409

    Image of Avocados (Persea americana) by B.navez, from the Wikimedia Commons under the Creative Commons Attribution-Share Alike 3.0 Unported, 2.5 Generic, 2.0 Generic and 1.0 Generic license.

  • Life Sciences Top 49

    By Donald Zuhn —

    IPO #2Last month, the Intellectual Property Owners Association (IPO) announced the release of its 36th annual list of the top 300 organizations receiving U.S. utility patents (see "Top 300 Organizations Granted U.S. Patents in 2018").  Patent Docs Readers may recall that the U.S. Patent and Trademark Office stopped releasing its annual list of top patent recipients in 2006 in order to "discourag[e] any perception that we believe more is better."

    The IPO compiled its list by counting the number of utility patents granted during 2018 that listed an organization or a subsidiary as the owner on the printed patent.  The IPO notes that patents that were granted to two or more organizations jointly were attributed to the organization listed first on the patent.  The IPO also noted that 307,759  patents were issued in 2018, which was an decrease from the 318,829 patents that issued in 2017.  The top fifteen companies on the IPO Top 300 are listed below (click on table to expand):

    Top 15
    Samsung Display Co., Ltd.; Sony Corp.; and Amazon Technologies, Inc. fell out of the Top 15 in 2018.  Samsung Display Co., Ltd. dropped from 11th to 17th; Sony Corp. dropped from 13th to 18th; and Amazon Technologies, Inc. dropped from 15th to 16th in 2018.  Jumping into the Top 15 were Dell Technologies; Ford Global Technologies, LLC; and United Technologies Corp.

    As in past years, Patent Docs used the IPO's list of top patent holders to compile a list of the top "life sciences" companies and organizations receiving U.S. utility patents in 2018.  Each organization's IPO top 300 ranking for 2018 is indicated in the "2018 IPO Rank" column; the IPO top 300 ranking for 2017 (if available) is indicated in the "2017 IPO Rank" column; and the change in number of patents from 2017 is indicated in "% Change from 2017."  The Life Sciences Top 49 is listed below (click on table to expand):

    LS Top 49

    Please note that some of the companies and organizations listed above may be involved in work outside the life sciences sector, and therefore, a portion of the patents granted to these companies and organizations may be directed to other than life sciences-related inventions.  In addition, our list includes medical device companies.

    For additional information regarding this topic, please see:

    • "IPO Releases List of Top 300 Patent Holders for 2017," July 4, 2018
    • "IPO Releases List of Top 300 Patent Holders for 2016," June 14, 2017
    • "IPO Releases List of Top 300 Patent Holders for 2014," July 1, 2015
    • "IPO Releases List of Top 300 Patent Holders for 2013," July 7, 2014
    • "IPO Releases List of Top 300 Patent Holders for 2012," June 24, 2013
    • "Another Look at IPO Top 300 and Life Sciences Top 53," June 11, 2012
    • "IPO Releases List of Top 300 Patent Holders for 2011," June 7, 2012
    • "IPO Releases List of Top 300 Patent Holders for 2010," June 30, 2011
    • "IPO Releases List of Top 300 Patent Holders for 2009," May 26, 2010
    • "IPO Releases List of Top 300 Patent Holders for 2008," May 14, 2009
    • "IPO Releases List of Top 300 Patent Holders," May 22, 2008
    • "IPO Posts List of Top 300 Patent Holders," April 20, 2007

  •     By Grant Shoebridge* —

    Australia Coat of ArmsIn July 1969, as a young boy, I watched in awe, along with the rest of world, as the United States of America put two men on the moon.  Years later in 2011, the then Prime Minister of Australia, Julia Gillard, stood before U.S. Congress and recalled the same moon-landing memory and with acquiescence wept that "Americans could do anything!"  Today, the U.S. seems to have entered, what was once described in an episode of Seinfeld as, "Bizzaro world" — Donald Trump is in the White House and, even more astonishingly, researchers are unable to protect what have been described judicially as "truly meritorious" and "ground breaking" innovations in the diagnostics and personal medicine space.  Today, it is Australia that reigns supreme over the U.S., as the Federal Court in Sequenom, Inc. v Ariosa Diagnostics, Inc. [2019] FCA 1011 (27 June 2019) confirmed that a non-invasive method of detecting fetal characteristics and abnormalities is patent eligible subject matter in Australia!

    Background

    The inventors of the patent-in-suit, Australian Patent No 727919, in the name of Sequenom, Inc., discovered that the cell-free fractions of a pregnant woman's blood contain surprisingly large amounts of cell-free fetal DNA (cffDNA).  Traditionally, this portion of the plasma or serum was discarded as medical waste.  This pioneering discovery led to the development of the claimed non-invasive method to determine fetal characteristics and abnormalities, such as Down syndrome.  Ariosa Diagnostics Inc, who sought to revoke Sequenom's Patent, conducts and licenses others to conduct a non-invasive prenatal diagnosis test, marketed under the name "Harmony", which Sequenom claims infringes their patent.

    The significance of the Australian Sequenom decision has been fueled by the corresponding U.S. case where the claims of Sequenom's patent were found to be patent ineligible because they were held to be directed to naturally-occurring matter.  The ensuing detrimental impact on U.S. diagnostics industry has subsequently resulted in a proposal for changes to the patentable subject matter legislation, which is currently being considered by US Congress.

    Issues and findings

    Under Australian law, patent eligibility is guided by the principles of the High Court's decision in National Research Development Corporation v Commissioner of Patents('NRDC') [1959] HCA 67.  In that landmark decision, it was held that subject matter was considered patent eligible if it was "an artificially created state of affairs" having "economic significance".

    Ariosa's case relied heavily on the approach that proved successful in the U.S., namely that the claims cover a mere discovery, that being the presence of cffDNA, which can be detected in the plasma or serum of pregnant women, and that the end result of each claim is not an artificially created state of affairs.  Ariosa further submitted that the claims involve nothing more than the use of well-known techniques to detect cffDNA in maternal blood.

    Ariosa also suggested that the Court should follow the U.S. position, which they suggested was in harmony with the Australian Myriad decision.  Judge Beach's response was an emphatic, "I hardly think so".  In fact, in considering the Australian High Court Myriad decision, Beach J emphasised the difference between the gene product claims considered in Myriad and the method defined in the claims of Sequenom's patent.  In particular, he stated that "in nature, the presence of cffDNA in the maternal blood has not and cannot be detected without human action.  Accordingly, unlike the claims considered in Myriad, the invention claimed adds to human knowledge and involves the suggestion of an act to be done which results in a new result, or a new process".

    The Court also agreed with Sequenom that the substance of the claimed method is distinct to simply the identification of a natural phenomenon, namely the presence of cffDNA in maternal blood.  This, the Judge said, is made clear by the patent specification, which explains that the invention offers a new approach for non-invasive prenatal diagnosis, which only occurs through human intervention and provides a significant advantage over existing fetal DNA detection methods, thus producing a result possessing economic utility.

    Consistency with foreign law

    Given the intense spotlight that has illuminated patentability issues in the U.S. for diagnostic methods in recent times, the consistency of the Australian decision and the corresponding UK proceedings between Ariosa and Sequenom (Illumina, Inc v Premaitha Health Plc[2017] EWHC 2930), will likely go unnoticed.  Those, however, looking for controversy in the conflicting Australian/U.S. findings should look no further than Judge Beach's swatting away of the issue by stating that the conclusion reached in the U.S. decision is problematic because of the U.S. Court's dissection of the claims into their constituent parts, which is contrary to Australia's NRDC and Myriad decisions — end of story.

    Conclusions

    This decision, and the recent decision in Meat & Livestock Australia Limited v Cargill, Inc [2018] FCA 51, make it clear that claims directed to practical applications of naturally-occurring phenomena, including gene sequences, used in methods of diagnosis and prognosis are patent eligible subject matter in Australia.  This will come as a welcome relief to the diagnostics and personal medicine industry and can be considered as "one small step" forward for Australian patent law but also, hopefully, "one giant leap" that influences beneficial change to the patent eligibility laws in the U.S.

    * Dr. Shoebridge is a Principal with Shelston IP.

  • By Kevin E. Noonan —

    CelgeneThe Federal Circuit affirmed a determination by the Patent Trial and Appeal Board (PTAB) that two patents owned by Celgene Corp. were invalid in Celgene Corp. v. Peter decided last week.  In rendering its decision, the Court also addressed on the merits Celgene's argument that retroactive invalidation of its patents under the inter partes review (IPR) procedures introduced into U.S. patent law by the Leahy-Smith America Invents Act is unconstitutional because its patents were granted before enactment of these IPR procedures and thus amounted to a taking under the Fifth Amendment.  The Court had avoided such constitutional challenges in earlier cases, most recently in Trading Technologies International, Inc. v. IBG LLC, 921 F.3d 1378 (Fed. Cir. 2019), on the grounds that in that case, TT's counsel had insufficiently raised and supported the argument.  Here, the Court found that Celgene's efforts had been "sufficiently thorough" as "a single constitutional issue [that] received thorough briefing from the parties and [was] addressed extensively at oral argument" for the panel to render a decision.  Predictably, that decision was to find that IPRs pass constitutional muster.

    CFADThe case arose from a challenge by the Coalition for Affordable Drugs VI LLC ("CFAD") of Celgene's U.S. Patent Nos. 6,045,501 and 6,315,720.  The PTAB determined that all claims of the '501 patent and claims 1-9 and 11-32 of the '720 patent were invalid for obviousness.  The patents are directed to methods for safely providing teratogenic agents, particularly thalidomide, to patients without risking distributing the drug to patients who are pregnant or at risk of becoming pregnant.  Claim 1 of the '501 patent and claim 1 of the '720 patent are representative; the technology embodied in the '501 patent was termed the "System for Thalidomide Education and Prescription Safety" and that embodied in the '720 patent was known as "Enhanced S.T.E.P.S.":

    '501 patent:

    1.  A method for delivering a teratogenic drug to patients in need of the drug while avoiding the delivery of said drug to a foetus comprising:
        a. registering in a computer readable storage medium prescribers who are qualified to prescribe said drug;
        b. registering in said medium pharmacies to fill prescriptions for said drug;
        c. registering said patients in said medium, including information concerning the ability of female patients to become pregnant and the ability of male patients to impregnate females;
       d.  retrieving from said medium information identifying a subpopulation of said female patients who are capable of becoming pregnant and male patients who are capable of impregnating females;
        e. providing to the subpopulation, counseling information concerning the risks attendant to fetal exposure to said drug;
        f. determining whether patients comprising said subpopulation are pregnant; and
        g. in response to a determination of non-pregnancy for said patients, authorizing said registered pharmacies to fill prescriptions from said registered prescribers for said non-pregnant registered patients.

    '720 patent:

    1.  In a method for delivering a drug to a patient in need of the drug, while avoiding the occurrence of an adverse side effect known or suspected of being caused by said drug, wherein said method is of the type in which prescriptions for said drug are filled only after a computer readable storage medium has been consulted to assure that the prescriber is registered in said medium and qualified to prescribe said drug, that the pharmacy is registered in said medium and qualified to fill the prescription for said drug, and the patient is registered in said medium and approved to receive said drug, the improvement comprising:
        a. defining a plurality of patient risk groups based upon a predefined set of risk parameters for said drug;
        b. defining a set of information to be obtained from said patient, which information is probative of the risk that said adverse side effect is likely to occur if said drug is taken by said patient;
        c. in response to said information set, assigning said patient to at least one of said risk groups and entering said risk group assignment in said medium;
        d. based upon said information and said risk group assignment, determining whether the risk that said adverse side effect is likely to occur is acceptable; and
        e. upon a determination that said risk is acceptable, generating a prescription approval code to be retrieved by said pharmacy before said prescription is filled.

    CFAD's obviousness contentions regarding the '501 patent asserted in support three scientific references on how to safely administer three teratogenic drugs:  thalidomide, isotretinoin (Accutane®), and clozapine.  For the "enhanced" system claimed in the '720 patent, CFAD asserted the thalidomide package insert; U.S. Patent No. 5,832,449; a scientific reference on "controlling and monitoring access to thalidomide"; and another scientific reference regarding mechanisms and significance of transfer of chemicals to animal and human semen.  Using rationales applying this art in varying combinations, the Board found that CFAD had established obviousness of all claims in the IPR except claim 10 of the '720 patent.  When CFAD declined to join Celgene's appeal, the Director of the U.S. Patent and Trademark Office intervened under 35 U.S.C. § 143.

    The Federal Circuit opinion was written by Chief Judge Prost, joined by Judges Bryson and Reyna.  On the merits regarding the '501 patent, the panel rejected Celgene's arguments on three points:  "(1) its finding that the prior art satisfies the 'computer readable storage medium,' limitation, which rises and falls with a claim construction argument; (2) its finding that it would have been obvious to counsel male patients about the risks of teratogenic drugs; and (3) its findings on secondary considerations."  On the first point, Celgene argued that the term should be limited to a centralized computer readable storage medium, which the Federal Circuit rejected because that was not what was recited in the claims of the '501 patent nor was that how the computer readable storage medium was described in the specification.  The panel also agreed with the PTAB that neither the prosecution history nor extrinsic evidence argued by Celgene supported this construction of the term.  In assessing the correctness of the Board's claim interpretation, the panel relied on the canon of claim construction that use of the indefinite article (a or an) in conjunction with the open claim term "comprising" indicates "one or more" of a particular term (here, the computer readable storage medium).  Nothing in the claim language, specification, nor prosecution history supported any exception to this general rule for construing claim terms, nor was there an unambiguous disclaimer of a non-centralized computer in the record, in the panel's opinion.  And the panel also affirmed the Board's refusal to allow Celgene's extrinsic evidence to "trump the persuasive intrinsic evidence in this case."

    Turning to the second point, the Federal Circuit agreed with the PTAB that providing information to male patients "capable of impregnating females" with information regarding the risks was obvious, based on CFAD's expert's testimony regarding how a person of ordinary skill would have understood one of the asserted prior art references (despite express teachings in another of the asserted references that "[n]o effects [of teratogenic drugs] on male sperm are recognized").  This teaching, in the context of the reference, referred to the contraceptive effects of thalidomide and not its teratogenic effects, according to the Board, and the Federal Circuit agreed.

    As to Celgene's objective indicia argument, Celgene challenged the Board's failure to credit its evidence of unexpected results and long-felt but unmet need.  The Federal Circuit rejected those challenges, substantially because the Court refused to reweigh the evidence on appeal.  The Court also did not find dispositive the "tension" between the Board's refusal to weigh the evidence in Celgene's favor as to the '501 patent, but finding the evidence persuasive regarding claim 10 of the '720 patent, because "[t]he fact that there is no long-felt, unmet need does not necessarily mean that there is no motivation to improve a system [as claimed in the '720 patent]," citing Spectrum Pharm., Inc. v. Sandoz Inc., 802 F.3d 1326, 1336 (Fed. Cir. 2015).

    The opinion then turned to the '720 patent.  Evidence of motivation used to support the Board's obviousness rejection of the claimed improved methods was the general motivation to "improve the existing distribution methods of potentially hazardous drugs because 'where significant safety risks exist with a drug, one would continuously search for safer ways to control the distribution of the drug.'"  The Federal Circuit agreed that the Board properly rejected Celgene's argument that there was no motivation to improve the S.T.E.P. system disclosed and claimed in the '501 patent because "there had been no reports of birth defects or even potential fetal exposure to thalidomide using that system."  The Court found that this motivation was not "generic" (as Celgene argued), based on the policy argument that "[i]n a case like this, where safety is a concern and where the potential adverse side effects are so severe, the Board did not err in finding that the desire to improve a system that is working well qualifies as a valid motivation."

    On more specific grounds, Celgene argued that even if there was generic motivation to improve its S.T.E.P. system, the Board erred by finding that the "particular, prospective, doctor-interfering system claimed by the '720 patent" was obvious (emphasis in opinion).  The Federal Circuit disagreed, finding that "the Board incorporated the notion of affirmative risk assessment [one of the particular limitations Celgene argued distinguished its claims from the cited art] into its claim construction and considered it in its obviousness findings."  The panel did not fault the Board's omission of the term "prospective" from its Final Written Decisions, because that term is not found in the contested claims, and rejected on similar grounds Celgene's arguments with regard to the limitation that the claimed enhanced system can "override" a physician's prescription.  Accordingly, the Federal Circuit affirmed the Board's determination that claims 1-9 and 11-32 of the '720 patent were obvious.

    On the constitutional issue, the panel first addressed whether reaching this issue was proper in this case, deciding that it was.  The basis for this portion of the Federal Circuit's opinion was that, despite the fact that Celgene made it argument for the first time on appeal, that was not improper and the Court had discretion to reach the issue in this limited circumstance.  Citing the "interest of justice" and the "growing number of retroactivity challenges following the Supreme Court's decision in Oil States" (where the Supreme Court raised without deciding the issue of whether an IPR could constitute a taking under the Due Process Clause or the Takings Clause), the timing of the Supreme Court's Oil States decision ("well after the Board's . . . final written decisions in the IPRs involved in this appeal") supported the Federal Circuit's decision to consider the question.  Other factors in favor of review include the question's status as a pure matter of law, and that even had Celgene raised the issue before the Board "it is unclear how the Board could have corrected the alleged constitutional defect . . . ."  (In a footnote, the opinion cites Supreme Court precedent that "adjudication of the constitutionality of congressional enactments has generally been thought beyon
    d the jurisdiction of administrative agencies," Elgin v. Dep't of Treasury, 567 U.S. 1, 16 (2012) (quoting Thunder Basin Coal Co. v. Reich, 510 U.S. 200, 215 (1994)).  Interestingly, the PTO at oral argument answered the question of whether the Board had the authority to address the constitutional argument by stating that "the Board could exercise its discretion to decline to institute the IPR," which as the Court notes, would be a decision unreviewable except possibly for mandamus.)  The Court thus found this "one of those exceptional circumstances in which our discretion is appropriately exercised to hear Celgene's constitutional challenge even though it was not raised below."

    On the merits, the panel based its decision that IPRs are not unconstitutional on the history, beginning in 1980, of Patent Office review of previously granted patents, which at least put patentees on notice that the Office could reconsider the validity of the patent grant.  This history made that grant contingent on there not being a successful post-grant challenge, and thus an IPR is nothing more than the latest iteration of such proceedings.  Characterizing IPRs in this way removed much of the force of the retroactivity argument, without which the constitutional challenge falls.  It is also consistent with the Court's decisions in Patlex Corp. v. Mossinghoff, 758 F.2d 594 (Fed. Cir. 1985), and Joy Technologies, Inc. v. Manbeck, 959 F.2d 226 (Fed. Cir. 1992), where the Court rejected similar challenges to ex parte reexamination.  (Happily, "[t]he PTO [did] not dispute that a valid patent is private property for the purposes of the Takings Clause.")  According to the opinion, "Celgene's pre-AIA patents were therefore granted subject to existing judicial and administrative avenues for reconsidering their validity" and "[f]or several decades [prior to Celgene applying for its patents], the Patent Office also possessed the authority to reexamine—and perhaps cancel—a patent claim that it had previously allowed."

    The Office also persuasively argued that invalidation of a patent is not an unconstitutional taking because "the patent owner 'never had a valid property right because the patent was erroneously issued in the first instance.'"  And of course the panel notes that "[t]he validity of patents has always been subject to challenge in district court," although there is (or should be) a distinction between the agency reversing itself within its own sphere of expertise and a court deciding that the agency had erred.

    In view of the similarities between IPRs and these earlier types of post-grant review proceedings, the panel states that:

    [I]t suffices for us to decide that IPRs do not differ sufficiently from the PTO reconsideration avenues available when the patents here were issued to constitute a Fifth Amendment taking.  Celgene identifies a number of differences between reexaminations and IPRs, including that IPRs are adjudicative and have discovery, briefing, and an oral hearing, . . . but as explained below [where the panel recites the many similarities between IPRs and earlier post-grant review proceedings], these differences are not sufficiently substantive or significant to constitute a taking."

    And the panel finds solace in several recent Supreme Court decisions, including SAS Inst., Inc. v. Iancu, 138 S. Ct. 1348, 1353 (2018), and Return Mail, Inc. v. United States Postal Serv., 139 S. Ct. 1853, 1860 (2019), for its decision that IPRs are not unconstitutional.

    One aspect of Celgene's argument that the panel did not expressly address is that an IPR "unfairly interferes with its reasonable investment-backed expectations without just compensation."  While this argument may not have gained any traction on patentee's behalf in this case, it does suggest that there is a class of individuals, namely investors, who may have a cognizable reliance interest that should be recognized and recompensed when a patent is invalidated in an IPR.  Investors, like patentees are on notice that patents can be invalidated in district court or before the Patent Office in post grant review proceedings in all their many flavors.  But the decision to invest rests at least in part on the investor relying on the presumption of validity, ensconced in statute and resting on the presumption that the Patent Office has properly granted a valid patent.  While infallibility is not one of the features of (or representations by) the Patent Office, as a part of the Federal government there should be a consequence in favor of relatively innocent by-standers when the government fails the public trust by improvidently granting invalid patents.  After all, inventions protected by patents do not satisfy their raison d'etre of "promoting progress" if these inventions are not commercialized, and commercialization requires investment.  Perhaps it would be fair to recognize that reliance interest and the injury to that interest by the Federal government declaring "do-over" (with frightening frequency, as Celgene argued), by creating a cause of action against the government to recoup at least some of an investor's losses occasioned by invalidation of presumptively valid patents.  In addition to the quality of justice that this would create, it might lessen the inhibitions (if not a distinct chill) to investment that the AIA's post-grant review proceedings have created.

    Celgene Corp. v. Peter (Fed. Cir. 2019)
    Panel: Chief Judge Prost and Circuit Judges Bryson and Reyna
    Opinion by Chief Judge Prost

  • By Michael Borella —

    Federal Circuit SealOn July 23, 2019, the Federal Circuit denied ChargePoint's request for panel rehearing and en banc review of its March 28, 2019 decision rendering four ChargePoint patents invalid under 35 U.S.C. § 101.  Since we did not review this case when the panel decision came down, and because the case subsequently garnered attention as being one of the more problematic § 101 decisions of late, today we provide a review and some perspective of the substantive issues at hand.

    ChargePoint sued SemaConnect in the District of Maryland, asserting infringement of U.S. Patent Nos. 8,138,715, 8,432,131, 8,450,967, and 7,956,570.  All four patents share the same specification.  SemaConnect moved for dismissal under Rule 12(b)(6) on the grounds that the patents failed to meet the eligibility requirements of § 101.  The District Court sided with SemaConnect.  ChargePoint appealed.

    2014's Alice Corp. vs. CLS Bank Int'l Supreme Court case set forth a two-part test to determine whether claims are eligible for patenting under § 101.  One must first decide whether the claim at hand involves a judicially-excluded law of nature, a natural phenomenon, or an abstract idea.  If so, then one must further decide whether any element or combination of elements in the claim is sufficient to ensure that the claim amounts to significantly more than the judicial exclusion.  But elements or combinations of elements that are well-understood, routine, and conventional will not lift the claim over the § 101 hurdle.  While this inquiry is generally carried out as a matter of law, factual issues can come into play when determining whether something is well-understood, routine, and conventional.

    As described by the Court, the focus of the claimed inventions is "charging stations for electric vehicles."  Traditionally, charging was a long, slow, one-way process that required parking overnight or for a long period of time.  ChargePoint's technology purported to solve two semi-related problems with this charging.  First, allowing restaurants, shopping centers, or apartment complexes to control access to vehicle chargers on their premises.  Second, allowing electric vehicles to transfer power to the electrical grid in times of high demand on the grid.  In the words of the Court:

    ChargePoint contends that its inventors created improved charging stations that address the various needs inherent in electric vehicle charging.  This was accomplished by creating networked charging stations.  According to ChargePoint, this network connectivity allows the stations to be managed from a central location, allows drivers to locate charging stations in advance, and allows all users to interact intelligently with the electricity grid.

    Claims 1 and 2 of the '715 patent recite:

    1.  An apparatus, comprising:
        a control device to turn electric supply on and off to enable and disable charge transfer for electric vehicles;
        a transceiver to communicate requests for charge transfer with a remote server and receive communications from the remote server via a data control unit that is connected to the remote server through a wide area network; and
        a controller, coupled with the control device and the transceiver, to cause the control device to turn the electric supply on based on communication from the remote server.

    2.  The apparatus of claim 1, further comprising an electrical coupler to make a connection with an electric vehicle, wherein the control device is to turn electric supply on and off by switching the electric coupler on and off.

    In addressing procedural aspects of the § 101 inquiry, the Court noted that "we have found the specification helpful in illuminating what a claim is 'directed to.'"  On the other hand, "while the specification may help illuminate the true focus of a claim, when analyzing patent eligibility, reliance on the specification must always yield to the claim language in identifying that focus."

    With that in mind, the Court rapidly concluded that "[i]t is clear from the language of claim 1 that the claim involves an abstract idea—namely, the abstract idea of communicating requests to a remote server and receiving communications from that server, i.e., communication over a network."  But this was insufficient to determine whether the focus of the claim was an abstract idea.  So the Court continued by looking to the specification to understand the problem being solved by the inventors.

    Reviewing its own precedent, the Court observed that statements made by the inventors in the specification can be used to determine this focus.  But hardware components described only at a high level of detail or functionally are generally outside of this focus.

    The problem facing the inventors, according to the Court, was "the lack of a communication network that would allow drivers, businesses, and utility companies to interact efficiently with the charging stations."  "From these statements," the Court concluded, "it is clear that the problem perceived by the patentee was a lack of a communication network for these charging stations, which limited the ability to efficiently operate them from a business perspective."  To further justify its interpretation, the Court observed that "the specification never suggests that the charging station itself is improved from a technical perspective, or that it would operate differently than it otherwise could . . . [n]or does the specification suggest that the invention involved overcoming some sort of technical difficulty in adding networking capability to the charging stations."  Thus, "the specification suggests that the invention of the patent is nothing more than the abstract idea of communication over a network for interacting with a device, applied to the context of electric vehicle charging stations."

    After establishing the problem to be solved, the Court turned to the language of the claims and found that it would "preempt the use of any networked charging stations."  The Court indicated that the breadth of the claims dictated such an expansive preemption, as the claims would effectively cover all solutions for achieving a desired result.

    To sum up the analysis of claim 1:

    In short, the inventors here had the good idea to add networking capabilities to existing charging stations to facilitate various business interactions.  But that is where they stopped, and that is all they patented.  We therefore hold that claim 1 is "directed to" an abstract idea.

    The Court shot down claim 2 on similar grounds, finding that the limitation of an "electrical coupler to make a connection with an electric vehicle" does not change the nature of the invention being claimed.  Thus, both claims are directed to an abstract idea.

    The Court applied a similar analysis to the claims of the other patents and came to the same outcome.  Indeed, the Court made the dangerously sweeping statement that "[c]ommunication over a network for [the purpose of device interaction] has been and continues to be a building block of the modern economy" — an abstract idea.  Undoubtedly, these words will be quoted over and over in future district court and Federal Circuit litigation in attempts to establish that any invention involving networked communication is per se ineligible under § 101.  Patent professionals are sadly shaking their heads at this all-too-likely and probably unintended consequence.

    In any event, the Court moved on to part two of the Alice test.  ChargePoint contended that it has presented factual allegations that, under Berkheimer v. HP, would preclude a Rule 12(b)(6) dismissal.  These included purported unconventional approaches involving "(a) the ability to turn electric supply on based on communications from a remote server; (b) a network-controlled charging system; and (c) a charging station that receives communication from a remote server, including communications made to implement a demand response policy."

    The Court's response — unfortunately predictable at this point — was that these innovations were directed to network control, which is the abstract idea itself.  To that end, the Court noted that "a claimed invention's use of the ineligible concept to which it is directed cannot supply the inventive concept that renders the invention 'significantly more' than that ineligible concept."

    The Court wrapped up:

    ChargePoint, of course, disagrees with this characterization, arguing that its patents claim "charging stations enabled to use networks, not the network connectivity itself."  But the specification gives no indication that the patented invention involved how to add network connectivity to these charging stations in an unconventional way.  From the claims and the specification, it is clear that network communication is the only possible inventive concept.  Because this is the abstract idea itself, this cannot supply the inventive concept at step two.

    Thus, the claims were ruled ineligible under § 101 and invalidated accordingly.

    Yes, the claims were broad.  Yes, they were vague, and the specification probably didn't describe the invention as well as it should have.  But for the 5,000th time, we have more well-founded and objective tests for these issues in §§ 102, 103, and 112.  Lumping obviousness and written description into § 101 results in the skewed analysis that you see here and in other eligibility decisions.

    And the outcome herein is indicative of the hazard associated with applying a variation of the "technical solution to a technical problem" test.  Sure, such a test has been used in Europe and other jurisdictions for quite some time.  But it is being used differently here (i.e., the problem and state of the art are based on statements in the specification rather than prior art, and the test is separate from the obviousness analysis).  As a result, the Federal Circuit is shooting more holes in the long-standing principle that the invention is defined by the claims.  Instead, the invention is now defined by a subjective evaluation of what a judge believes to be the problem being solved, and then this identified problem is used to color the interpretation of the claims under § 101.  If the problem is viewed as non-technical, then the claims can easily be found abstract, as was the case with ChargePoint.  The fact that the Federal Circuit has previously found claims that solve business problems to be eligible under § 101 (e.g., DDR Holdings v. Hotels.com) seems to be beside the point.

    The ensuing cognitive dissonance — ChargePoint's device-oriented claims being viewed as abstract — illustrates the judicial-exception-creep that has been occurring since Alice.  Since the § 101 inquiry can be applied in an outcome oriented fashion, more and more non-abstract devices, systems, structures, and components are now being lumped into the abstract idea classification or ignored as "conventional" in part two of the Alice test.  The abstract idea exception is a legal fiction that has been expanded to the point of meaninglessness — thinking about network communication is truly abstract, but actual network communication or the facilitation thereof is not.

    Indeed, the language of the claims matter little when one can try to infer from the specification what the claims "really mean" and then analyze that ascribed meaning rather than what the claims actually recite.  The door is left open for bad actors to try to convince the judiciary that virtually everything involving a computer, software, or a network is abstract.  At what point do we realize that, as just one example, the little computers we carry around in our pockets use software in a tangible fashion to communicate and have a concrete impact on themselves and other devices?  At what point does the legal fiction of the abstract idea swallow all of patent law?  Hint: this case.

    ChargePoint Inc. v. SemaConnect Inc. (Fed. Cir. 2019)
    Per Curiam

  • CalendarAugust 6, 2019 – "Section 101 Litigation After Cellspin" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    August 15, 2019 – Technology Center 2800 customer partnership meeting (U.S. Patent and Trademark Office) – 11:30 am to 4:30 pm (ET) on 

    August 20, 2019 – "Section 101 Reform: Prospects and Pitfalls" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    October 3-4, 2019 – Paragraph IV Disputes Master Symposium (American Conference Institute) – Chicago IL

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Section 101 Litigation After Cellspin" on August 6, 2019 from 2:00 to 3:00 pm (ET).  Maxine Graham of American Express, Larry Hadley of Glaser Weil, and Kevin Rodkey of Finnegan will provide tools and insights on courtroom tactics for litigating patent eligibility issues, and discuss:

    • New strategies for patent owners that start with the infringement complaint;
    • Ways defendants can counter plaintiff's attempts to create factual disputes; and
    • Maintaining maximum flexibility for clients in an unpredictable environment.

    The registration fee for the webinar is $135 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.